Most common infection in prostate biopsy was E. coli, followed by mild bleeding.
Combining testing of urinary T2:ERG, PCA3 at thresholds that detected aggressive prostate cancer improved specificity from 18% to 39%.
But PSA density and body mass index are associated with prostate cancer reclassification.
In a study, systematic biopsy detected clinically significant prostate cancer in only 3% of men with negative findings on multiparametic MRI.
In multiparametric magnetic resonance imaging, rectal distension have a negative effect on T2-weighted and diffusion-weighted images.
Using imaging to triage men with elevated PSA might avoid a quarter of unnecessary biopsies, according to a study.
In a study, only 3 of 108 patients experienced complications, all of which were minor and required no hospitalization or further intervention.
Patients on active surveillance with stable disease at the time of initial surveillance prostate biopsy may be appropriate candidates for less intensive surveillance prostate biopsy schedules.
In patients undergoing confirmatory biopsy for active surveillance, MRI can increase detection of clinically significant tumors compared with standard systematic biopsy.
PITX2 methylation was increased in tumor-positive biopsies.
When MRI-US fusion biopsy is added to the standard 12-core biopsy, the number of men eligible for active surveillance decreases, study finds.
Magnetic resonance imaging of the prostate missed 13% of high-grade cancers that were later found on transrectal ultrasound-guided biopsy.
Patients are at higher risk with the transrectal rather than transperineal approach.
Following the 2012 USPSTF recommendation against PSA screening in populations, rates of radical prostatectomy and biopsy have become significantly less common.
Incident prostate cancer cohorts were defined by examining men who were regularly screened from the placebo arms of two large prostate cancer prevention trials.
After 20 years, the prostate cancer mortality rate was 0.7% for men with a PSA level of 10 ng/mL or less and benign initial biopsy results.
The development of this scale, once further validated, will give clinicians the ability to verify lupus nephritis activity without the need for an invasive kidney biopsy.
Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.
In a study, use of the medication was associated with a significant 61% decreased risk.
The proportion of biopsied men who have complications from the procedure rose from 14% to 18% from 2005 to 2014.
Detection of high Gleason grade tumors is not significantly improved versus standard 12-core biopsy.
Between renal mass biopsy, surgical pathology, rate of accuracy in identifying malignancies 97.1%.
Antibiotics selected based on results of pre-biopsy rectal swab cultures.
Prostate-specific antigen density, total tumor length are significant predictors.
Men with a normal PSA upon repeat testing had a 78% lower risk of prostate cancer diagnosis than men with a second abnormal PSA result.
More high-grade cancers detected with MRF-TB vs. systematic biopsy in men undergoing primary biopsy.
Relatively few men with atypical small acinar proliferation are found to have high-grade prostate cancer on repeat biopsy.
Small study demonstrates the promise of PET-CT using a radiotracer that targets the prostate-specific membrane antigen.
The technique, with cognitive assistance, identified recurrent tumors in 80% of patients.
PNI in prostate biopsy specimens are associated with an 11-fold increased risk of bone metastasis.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)